>>In pre-clinical tests (animal and human), Targretin and LGD1268 has been shown
to synergize with Resulin and Avandia and I suspect that it synergizes with the Actos
also.
LGND also has its own TZD program, which is being developed in part with LLY
support. Looks like LGND is in the right place at the right time (Targretin and
LGD1268 synergize with Tamoxifen, and Evista and probably Droloxifene,
CP-366,156, and TSE424 in the SERM category for treatment and prevention of
breast cancer and osteoporosis, and the rexinoids also synergize with Resulin,
Avandia, and probably Actos and other TZDs in the TZD category for diabetes and
other metabolic diseases like obesity. Sounds like Avandia, Actos, and Targretin
will be available next year.<<
henry, let's say that these synergies are factual. how long until these drugs could be used together on a mass scale? also, how big are the ontak and targretin markets that we expect approval for? tia... |
